Objective We compared the efficacies of irbesartan and olmesartan after successful stent implantation in patients with stable angina. Methods Twenty-six patients were randomly divided into irbesartan and olmesartan groups and treated for approximately eight months (at follow-up coronary angiography). Results There were no differences in blood pressure (BP) reduction or late loss between the groups. The BP levels in both groups at follow-up were significantly reduced. The equality of variance of systolic (S)BP (i.e., the intragroup standard deviation of SBP) in the irbesartan group was significantly smaller than that observed in the olmesartan group at follow-up. In addition, log[pentraxin-3] was significantly decreased in all of the patients at follow-up, with no differences between the groups. Interestingly, the levels of log[highsensitive C-reactive protein(hs-CRP)] measured at 0 weeks were positively associated with in-stent late loss, and among independent biochemical variables in addition to age, gender, body mass index and the kind of angiotensin receptor blockers at 0 weeks, only these levels were related to in-stent late loss, as assessed by a multivariate analysis. Conclusion The ability of irbesartan to reduce BP is comparable to that of olmesartan, and irbesartan exhibits a lower variance of systolic BP after treatment. The level of log[hs-CRP] before stent implantation is a predictor of in-stent late loss.
Introduction
Angiotensin II (Ang II) type 1 receptor blockers (ARBs) are highly selective for the Ang II type 1 (AT1) receptor, a member of the G protein-coupled receptor superfamily, and block the diverse effects of Ang II (1) . ARBs are some of the most popular anti-hypertensive agents in the world. Since blood pressure (BP) is not adequately controlled in two-thirds of patients under monotherapy (2) , intensive therapy is needed to achieve control of BP. There is no clear evidence regarding whether lowering BP is beneficial for re-pan. Over the past several years, the efficacies of ARBs have been compared, and differences have been observed as pleiotropic effects in addition to the ability of the drugs to lower BP (5) . The in-stent late loss and decrease in % diameter stenosis (DS) under treatment with valsartan are significantly lower than those achieved with losartan as assessed by quantitative coronary angiography (QCA) after six months in patients with acute myocardial infarction (6) . We also previously compared the efficacy and safety of irbesartan to that of olmesartan in patients with hypertension (HT) (7) . Although the BP reduction observed in the irbesartan group was similar to that observed in the olmesartan group, the equality of variance of BP (i.e., the intragroup standard deviation of BP) in the irbesartan group was significantly smaller than that observed in the olmesartan group (7) . In addition, the blood concentrations of adiponectin were significantly increased in the irbesartan group, and a marker of inflammation, pentraxin (PTX)-3, the was significantly decreased in the irbesartan group.
Therefore, we compared the efficacy of irbesartan to that of olmesartan in patients undergoing coronary stent implantation. We also analyzed whether inflammatory markers [high-sensitive C reactive protein (hs-CRP), PTX-3 and monocyte chemotactic protein-1 (MCP-1)] associated with the prevention of coronary restenosis decrease by ARBs.
Materials and Methods

Patients
The subjects included 26 patients with stable angina who underwent successful coronary stent implantation at Fukuoka University Hospital. The patients were randomly divided into irbesartan and olmesartan groups. When the BP level was ! 140/90 mmHg without ARB treatment at baseline, the patient initially received irbesartan (50-100 mg/day) or olmesartan (10-20 mg/day). When the BP level was <140/90 mmHg under ARB therapy, we applied a changeover of ARBs, switching from the prior ARB to irbesartan or olmesartan as an equivalent. If the BP level was ! 140/90 mmHg under ARB therapy, we switched from the prior ARB to a higher dose of irbesartan or olmesartan. Although the use of combined treatment with other antihypertensive drugs was permitted, the doses of those drugs were not changed and other antihypertensive drugs were not added throughout the study period. All patients received aspirin and ticlopidine or clopidogrel throughout the study period. Follow-up coronary angiography was performed after stenting (mean period: 240 ± 55 days). We measured BP, QCA and biochemical parameters at 0 weeks and during the follow-up.
Patients who had suffered a stroke within the previous six months, had renal [serum creatinine (Cr) more than 2 mg/ dL] or liver dysfunction [serum aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) levels more than 2-fold higher than the normal range], were pregnant or were hypersensitive to irbesartan or olmesartan were excluded from the study. Our protocol was approved by the hospital ethics committee and written informed consent was obtained from all patients.
BP and biochemical parameter measurements
BP was measured in the right arm after a 5-minute rest period, and the average of three consecutive BP measurements was used. Patients with systolic (S)BP or diastolic (D)BP ! 140/90 mmHg or who were under antihypertensive treatment were considered to have HT. We also examined biochemical parameters, including complete blood cell counts, the liver function [AST, ALT], the renal function [blood urea nitrogen (BUN), Cr and cystatin (Cys)-C], lipid profiles [total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG)], glucose, uric acid (UA), electrolytes [serum sodium (Na), potassium (K) and chloride (Cl)], hs-CRP, PTX-3 and MCP-1. Blood samples were collected following an overnight fast using standard techniques. The concentrations of MCP-1 and PTX-3 in plasma were determined in duplicate using specific enzyme immunoassays according to the manufacturer's instructions (R&D Systems, Minneapolis, MN, and Perseus Proteomics Inc., Tokyo, Japan). At our laboratory, the intra-and inter-assay coefficients of variation for these parameters were each <5%.
Patients with an LDL-C level ! 140 mg/dL, a TG level ! 150 mg/dL or an HDL-C level <40 mg/dL or who were under treatment for dyslipidemia (DL) were diagnosed with DL. Patients who were being treated for diabetes mellitus (DM) or who had symptoms of DM and a fasting blood glucose concentration ! 126 mg/dL were considered to have DM. Otherwise, the results of a 75-g oral glucose tolerance test were used to diagnose DM.
QCA
QCA was performed on all qualifying angiograms at the angiographic core laboratory at Fukuoka University Hospital using CMS (MEDIS, The Netherlands) immediately before and after the procedure (pre) and at follow-up. A QCA analysis was performed in the in-stent area, the overlapped site and the in-segment area, which included the stented segment as well as the margins (5 mm) proximal and distal to the stent. Restenosis was defined as >50% diameter stenosis on follow-up angiography.
Statistical analysis
The statistical analysis was performed using the Stat View statistical software package (Stat View 5; SAS Institute Inc., Cary, NC, USA) at Fukuoka University (Fukuoka, Japan). The data are shown as the mean ± standard deviation. Categorical variables were compared between groups using a chi-square analysis or Fisher's exact test. The differences in continuous variables between groups were examined using Student's t-test or Wilcoxon's rank-sum test. A multivariate analysis was performed using a logistic regression analysis for independent variables that were related to in-stent late loss. Differences were considered to be statistically significant when the p values were <0.05.
Results
Baseline patient characteristics
Twenty-six patients were enrolled and randomly divided into irbesartan and olmesartan groups. Two patients withdrew from the study due to elevation of BP during the study period (n=1) and not visiting the hospital (n=1). Therefore, we ultimately analyzed data for 24 patients (irbesartan group, n=11; olmesartan group, n=13). Table 1 shows the clinical characteristics of the 24 total patients. The patients either initially received ARBs (n=11) or a changeover of ARBs (n=13). The patients who received a changeover had taken telmisartan (n=4, 35 ± 10 mg/day), losartan (n=4, 44 ± 38 mg/day), olmesartan (n=3, 17 ± 6 mg/day), candesartan (n=1, average dose: 4.0 mg/day) or valsartan (n=1, 20 mg/day) before the study. At baseline, the average doses of ARBs in the irbesartan and olmesartan groups were 86 ± 45 mg/day and 18 ± 11 mg/day, respectively. Several coronary risk factors, such as smoking, DM and DL, but not gender, were similar in the two groups. There were no significant differences in the use of medications such as β-blockers, calcium-channel blockers, statins or nicorandil between the groups.
Changes in BP and PR during the study period Fig. 1 shows the changes in BP that occurred during the study period. There were no differences in BP at baseline between the irbesartan and olmesartan groups. SBP was significantly reduced at 4, 8 and 12 weeks and at follow-up in patients who initially received irbesartan, as was diastolic blood pressure (DBP) at 8 weeks and follow-up. BP was not significantly decreased in patients who received a changeover to irbesartan or olmesartan. In addition, there were no changes in pulse rate (PR) in any of the groups throughout the study period (data not shown).
Since the S.D. value of SBP at follow-up in the irbesartan group (116 ± 6 mmHg, mean± S.D.) was lower than that observed in the olmesartan group (117 ± 12), the equality of variance of SBP between the irbesartan and olmesartan groups at 0 weeks and follow-up was analyzed using Bartlett's test. While there were no differences in the equality of variance of SBP between the irbesartan (139 ± 17) and olmesartan (130 ± 16) groups at 0 weeks (p=0.909), the equality of variance in the irbesartan group was significantly smaller than that observed in the olmesartan group at follow-up (p=0.029).
Angiographic characteristics at baseline and follow-up
Among the angiographic characteristics observed at baseline, there were no significant differences regarding vessel disease, target vessels, lesion complexity or lesion length between the irbesartan and olmesartan groups ( Table 2 ). There were also no significant differences in the type of stent. The angiographic characteristics at follow-up are shown in Table 2. No significant differences were observed in reference diameter, in-stent late loss or in-stent % DS between the irbesartan and olmesartan groups. In addition, there were no significant associations between in-stent late loss and reductions in SBP (r=0.008, p=0.972) or DBP (r=0.111, p=0.605) after ARB treatment. Major adverse cardiac events (MACE) were defined as cardiac death, Q wave myocardial infarction (MI) or TLR occurring during the study period. There were no cardiac deaths or MIs. The TLR rates in the irbesartan and olmesartan groups were 0% and 8%, respectively, with no significant differences between the groups.
Biochemical parameters in blood at baseline and follow-up
The biochemical parameters in blood at baseline and follow-up are shown in Table 3 . All of the parameters expect for LDL-C, including the AST, ALT, Cr, UA and HbA1c concentrations, at baseline and follow-up were similar between the irbesartan and olmesartan groups. The levels of LDL-C measured at follow-up were significantly lower than those measured at baseline in the olmesartan group. With regard to biomarkers of inflammation, log[PTX-3] was significantly decreased and log[hs-CRP] tended to be decreased in all of the patients at follow-up, with no differences between the groups (Fig. 2a, b) .
Predictors of late loss among inflammatory markers
The levels of log[hs-CRP] at 0 weeks were positively as- (Fig. 2c) . Therefore, a multivariate analysis was performed using a logistic regression analysis of independent variables (biochemical markers such as hs-CRP, PTX-3, MCP-1 and cystatin C at 0 weeks in addition to age, gender and kind of ARB) that were related to in-stent late loss. The levels of log[hs-CRP] at 0 weeks (p= 0.038) were related to in-stent late loss only (Table 4) .
Discussion
In the present study, there were no differences in BP reduction or in-stent late loss between the irbesartan and olmesartan groups, and the BP levels in both groups at follow-up were significantly reduced and reached the target BP. The irbesartan group exhibited a lower variance of SBP after treatment. In addition, only the levels of log[hs-CRP] before stent implantation were significantly associated with in-stent late loss.
There were no differences in BP reduction between the treatment groups. The average doses of irbesartan and olmesartan were 86 and 18 mg/day, respectively. Since the ability of irbesartan to reduce BP was equal to that of olmesartan, the ability of a medium dose of irbesartan (100 mg/day) to reduce BP may be similar to that of a medium dose of olmesartan (20 mg/day). We previously reported that the ability of irbesartan to reduce BP after treatment for 12 weeks is at least comparable to that of olmesartan with equivalent safety (7) . The present study also showed a similar result after more long-term treatment for approximately eight months. In addition, irbesartan exhibited a lower variance of BP at 12 weeks, which indicates that it may be more effective than olmesartan for most patients (7). Irbesartan was also associated with a lower variance of SBP at eight months. There are several possible explanations for this difference in the variance of SBP, which we have discussed in our previous report (7) . First, the unique binding behavior of irbesartan is different from that of olmesartan. Olmesartan medoxomil is a prodrug that is rapidly hydrolyzed into olmesartan in the gastrointestinal tract (8), In-stent late loss whereas irbesartan has no active metabolite. It is cleared predominantly by the bile and partly by the kidneys (9) . Moreover, irbesartan is distributed over a large volume. Although both groups exhibited significant reductions in BP, there were no significant associations between in-stent late loss and changes in SBP or DBP after eight months. Moreover, there were no differences in in-stent late loss between the groups. In-stent restenosis primarily occurs due to excessive neointimal formation (10) . All ARBs do not have the same effects (5). We previously reported that valsartan is associated with a significant reduction in late loss compared to losartan (6) . High-dose candesartan cilexetil therapy does not reduce restenosis rates (11) . The late loss rates in the irbesartan and olmesartan groups were 0.31 and 0.41, respectively, which were relatively lower than that reported in a previous study (11) . Since most patients in the present study received drug eluting stent (DES) implantation (approximately 63%), there may be no differences in late loss.
Inflammation plays a pathological role in the progression of atherosclerosis. We previously reported that ARB therapy is associated with a significant reduction in the levels of PTX-3 in the blood in patients with coronary artery disease or HT (3, 7) . In this study, we confirmed this point and found that log[PTX-3] was significantly decreased in all of the patients at follow-up. On the other hand, there were no differences between the groups. This may be due to insufficient statistical power due to the small number of patients. Interestingly, the levels of log[hs-CRP] at 0 weeks were positively associated with in-stent late loss and were related to late loss only, whereas we included several biomarkers (PTX-3, MCP-1 and cystatin C in addition to hs-CRP) as independent biochemical variables. There have been many reports on the association between hs-CRP and coronary restenosis. For example, Finn et al. reported that hs-CRP is the only predictor of angiographic progression (12) . Higher plasma levels of CRP at 72 hours after stenting are associated with higher late loss both in-stent and in-segment in patients undergoing paclitaxel-eluting stent implantation (13) . The plasma hs-CRP level may independently predict in-stent restenosis both at admission and at follow-up in stable angina patients undergoing coronary DES implantation (14) . Although the relative increase in the level of PTX-3 24 hours after coronary stenting is the most powerful predictor of late lumen loss (15) , no previous reports have compared the usefulness of hs-CRP with that of PTX-3 with regard to coronary restenosis. This study is the first to suggest that the hs-CRP levels may be a more critical biomarker for predicting in-stent restenosis. In this study, the olmesartan group exhibited significant reductions in the LDL-C levels. Although there were no differences in the percentage of statin treatment between the irbesartan and olmesartan groups, several patients initially received statin treatment (three patients in the irbesartan group and five patients in the olmesartan group). In addition, ARBs have been shown to decrease the levels of total cholesterol and LDL-C in patients with HT (16) . Ang II stimulates the macrophage hydroxymethylglutaryl-CoA (HMGCoA) reductase gene expression (17) , and several ARBs activate peroxisome proliferator-activated receptor-γ, which regulates lipid metabolism (18) . However, further studies are needed to establish a relationship between ARBs and improved lipid metabolism.
Study limitations
There are several limitations associated with the present study. The main limitation is the small number of patients evaluated in an open-label, single-center study design. The present study was randomized but not placebo-controlled or blinded. The effects of BP-lowering by ARBs should be confirmed in a double-blind, large, randomized multicenter study. Second, this study included patients who either initially received ARBs or a changeover of ARBs, including patients who received olmesartan but not irbesartan. This may have biased the results. Third, intravascular ultrasound data were not available in this study. In addition, a longer study period is needed to determine whether there are clear differences between ARBs.
Conclusion
The ability of irbesartan to reduce BP is comparable to that of olmesartan, and irbesartan exhibits a lower variance of systolic BP after treatment. The levels of log[hs-CRP] before stent implantation are significantly associated with instent late loss only.
